International Journal of Hematology

, Volume 75, Issue 4, pp 434–439 | Cite as

Diagnostic Significance of Measurement of the Receptor for Urokinase-Type Plasminogen Activato on Granulocytes and in Plasma from Patients with Paroxysmal Nocturnal Hemoglobinuria

  • Weiqiang Gao
  • Zhaoyue Wang
  • Xia Bai
  • Yuyun Li
  • Changgeng Ruan
Case Report


Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired stem cell disorder characterized by the deficiency of all proteins anchored to the membrane by the glycosyl-phosphatidylinositol (GPI) anchor. The receptor for urokinase-type plasminogen activator (uPAR) also is attached to the cell membrane by a GPI anchor, and that soluble uPAR (suPAR) is present in plasma. In the present study, we measured uPAR, CD55, and CD59 on granulocytes by means of flow cytometry and suPAR in plasma by means of immunoradiometric assay. The subjects were 20 patients with PNH, 59 other patients with anemia, and 21 healthy individuals. In patients with PNH, both the mean fluorescence intensity and the positive percentage of fluorescence-activated granulocytes of uPAR, CD55, and CD59 were remarkably decreased, whereas in patients with other forms of anemia, except 2 patients with aplastic anemia, the results were not altered in comparison with those for the healthy individuals. The level of uPAR was reduced to the same extent as were those of CD55 and CD59 on the PNH-affected granulocytes. Some peak shape abnormalities (double peaks, peak tailing, or both) in the histogram of fluorescence intensity were also found in patients with PNH. The suPAR concentration of PNH plasma was 4.04 ± 2.47 ng/mL, which was higher than that of the healthy individuals, 1.73 ± 0.96 ng/mL (P < .01). The positive percentage of fluorescence-activated granulocytes was inversely associated with the plasma suPAR level in patients with PNH (r = -0.79, P < .01). Our data suggest that measurement of uPAR on granulocytes by means of flow cytometry and of suPAR in plasma by means of immunoradiometric assay are specific techniques for the diagnosis of PNH.

Key words

Paroxysmal nocturnal hemoglobinuria Urokinase-type plasminogen activator receptor Granulocyte Plasma Diagnosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yeh ETH, Rosse WF. Paroxysmal nocturnal hemoglobinuria and the glycosylphosphatidyl-inositol anchor.J Clin Invest. 1994;93: 2305–2310.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria.Cell. 1993;73:703–711.CrossRefPubMedGoogle Scholar
  3. 3.
    Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis.Science. 1993; 259:1318–1320.CrossRefPubMedGoogle Scholar
  4. 4.
    Bessler M, Mason PJ, Hillmen P, et al. Paroxysmal nocturnal hemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.EMBO J. 1994;13:110–117.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Armstrong C, Schubert J, Ueda E, et al. Affected paroxysmal nocturnal T lymphocytes harbour a common defect in assembly of N-acetyl-D-glucosamine inositol phospholipid corresponding to that in class A Thy-1-murine lymphoma mutants.J Biol Chem. 1992; 267:25347–25351.PubMedGoogle Scholar
  6. 6.
    Hillmen P, Bessler M, Mason PJ, et al. Specific defect in N-acetylglucosamine incorporation in the GPI anchor synthetic pathway in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria.Proc Natl Acad Sci U S A. 1993;90:5272–5276.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Rosse WF, Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria.Blood. 1995;86:4650–4655.Google Scholar
  8. 8.
    Rosti V. The molecular basis of paroxysmal nocturnal hemoglobinuria.Haematologica. 2000;85:82–87.PubMedGoogle Scholar
  9. 9.
    Shichishima T, Terasawa T, Saitoh Y, Hashimoto C, Ohto H, Maruyama Y. Diagnosis of paroxysmal nocturnal hemoglobinuria by phenotypic analysis of erythrocytes using two-color flow cytometry with monoclonal antibodies to DAF and CD59/MACIF.Br J Haematol. 1993;85:378–385.CrossRefPubMedGoogle Scholar
  10. 10.
    Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria.Blood. 1996;87:5332–5340.PubMedGoogle Scholar
  11. 11.
    Plesner T, Ralfkiær E, Wittrup M, et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue.Am J Clin Pathol. 1994;102: 835–841.CrossRefPubMedGoogle Scholar
  12. 12.
    Ploug M, Eriksen J, Plesner T, Hansen NE, Danø K.A soluble form of the glycolipid-anchored receptor for urokinase-type plasmino-gen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. øEur J Biochem. 1992;208:397–404.Google Scholar
  13. 13.
    Ploug M, Plesner T, Rønne E, et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria.Blood. 1992;79:1447–1455.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Rønne E, Pappot H, Grøndahl-Hansen J, et al. The receptor for urokinase-type plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal hemoglobinuria.Br J Haematol. 1995;89:576–581.CrossRefPubMedGoogle Scholar
  15. 15.
    Bai X, Xi X, Xu J, Ruan C. Preparation and identification of monoclonal antibodies against human urokinase receptor.Acta Acad Med Suzhou. 1999;19:1268–1270.Google Scholar
  16. 16.
    Hsi ED. Paroxysmal nocturnal hemoglobinuria testing by flow cytometry: evaluation of the REDQUANT and CELLQUANT kits.Am J Clin Pathol. 2000;114:798–806.CrossRefPubMedGoogle Scholar
  17. 17.
    Gao W, Wang Z, Bai X, Xi X, Ruan C. Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients.Thromb Res. 2001;102:25–31.CrossRefPubMedGoogle Scholar
  18. 18.
    Zhang ZN, Guo WH, Liu EK. Clinical experience in the diagnosis for paroxysmal nocturnal hemoglobinuria.Chin J Intern Med. 1995;34:540–542.Google Scholar
  19. 19.
    Rosse WF. Paroxysmal nocturnal hemoglobinuria. In: Hoffman R,Benz EJ Jr, Shattil SJ, et al., eds.Hematology: Basic Principles and Practice. New York: Churchill Livingstone; 2001:331–342.Google Scholar
  20. 20.
    Pakdeesuwan K, Wanachiwanawin W, Siripanyaphinyo U, Pattana-panyasat K, Wilairat P, Issaragrisil S. Immunophenotypic discrepancies between granulocytic and erythroid lineages in peripheral blood of patients with paroxysmal nocturnal haemoglobinuria.Eur J Haematol. 2000;65:8–16.CrossRefPubMedGoogle Scholar
  21. 21.
    Piedras J, Lopez-Karpovitch X. Flow cytometric analysis of glyco-sylphosphatidyl-inositol-anchored proteins to assess paroxysmal nocturnal hemoglobinuria clone size.Cytometry. 2000;42:234–238.CrossRefPubMedGoogle Scholar
  22. 22.
    Schrezenmeier H, Hildebrand A, Rojewski M, Hacker H, Heimpel H, Raghavachar A. Paroxysmal nocturnal haemoglobinuria: a replacement of haematopoietic tissue?Acta Haematol. 2000;103: 41–48.Google Scholar
  23. 23.
    Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the uPA-uPAR-PAI-1 system.Thromb Haemost. 1999;82:298–304.CrossRefPubMedGoogle Scholar
  24. 24.
    Pedersen TL, Yong K, Pedersen JO, Hansen NE, Danø K, Plesner T. Impaired migration in vitro of neutrophils from patients with paroxysmal nocturnal hemoglobinuria.Br J Haematol. 1996;95: 45–51.PubMedGoogle Scholar
  25. 25.
    Ninomiya H, Hasegawa Y, Nagasawa T, Abe T. Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cellassociated fibrinolytic activity.Int J Hematol. 1997;65:285–291.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Weiqiang Gao
    • 1
  • Zhaoyue Wang
    • 1
  • Xia Bai
    • 1
  • Yuyun Li
    • 1
  • Changgeng Ruan
    • 1
  1. 1.Thrombosis and Hemostasis Research UnitJiangsu Institute of Hematology, First Affiliated Hospital of Suzhou UniversitySuzhou, JiangsuChina

Personalised recommendations